Abeona Therapeutics Inc.
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF (Salt Diafiltration) ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse, for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse, for the treatment of rectal mucositis and radiation proctitis. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and EB Research Medical Foundation that focus on gene therapy treatments for epidermolysis bullosa, a group of rare genetic skin disorders impacting children characterized by skin blisters and erosions over the body. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.